Helene Visit 1: An Elderly Female with Stage IIIA Non–Small-Cell Lung Cancer

Title:

Helene Visit 1: An Elderly Female with Stage IIIA Non–Small-Cell Lung Cancer

Topic: Hematology-Oncology
Relevant Terms: Non–Small-Cell Lung Cancer
Primary Audience: Medical oncologists; surgical oncologists; radiation oncologists; clinical pathologists; and other health care professionals involved in the care and treatment of patients with NSCLC
Launch Date: 23-Aug-10
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Non–Small-Cell Lung Cancer: Current Advances in the Treatment

Learning Objectives

Upon completion of the activity, participants should be able to:

  1. Interpret the current advances in treatment from clinical trial results to adjust practices to best possible care based on latest data available
  2. Assess the clinical efficacy of new agents and combinations
  3. Apply appropriate treatment strategies to complex case scenarios, such as patients who have various comorbidities, poor performance status, or treatment-related side effects
  4. Identify subsets of patients who may benefit from treatment with targeted agents

    Faculty

    Mary Pinder-Schenck, MD
    Assistant Member
    Thoracic Oncology
    H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida
    Jared Weiss, MD
    Assistant Professor of Medicine
    University of North Carolina
    Division of Hematology and Oncology
    Chapel Hill, North Carolina
    Howard L. West, MD
    Medical Director, Thoracic Oncology Program
    Swedish Cancer Institute
    President & CEO
    Global Resource for Advancing Cancer Education
    Seattle, Washington
    Non–Small-Cell Lung Cancer Clinical Decision Points: Virtual Patient Cases
     
    Release date: August 23, 2010
    Expiration date: August 23, 2011
    Estimated time to complete activity: 0.5 hours
     
    Jointly sponsored by Curatio CME Institute and H. Lee Moffitt Cancer Center & Research Institute 
     
    Support for this activity has been provided through an educational grant from Lilly.
     
    Activity Overview
    Non–small cell lung cancer (NSCLC) tumors are heterogeneous. Thus, patients with similar clinical stage and tumor histology can have vastly different clinical outcomes and responses to treatment, underscoring the need for individualized therapy. Concurrent radiation and chemotherapy is the standard of care for patients with unresectable stage IIIA and IIIB NSCLC. For patients with stage IV NSCLC, chemotherapy and targeted therapies are the mainstay of treatment. However, selection of the initial treatment regimen is complicated by the variety of options available. Determining the appropriate regimen is further complicated in certain subgroups of patients, such as those with poor performance status or comorbidities, because minimal guidance is given in current guidelines. The introduction of targeted agents, such as inhibitors of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), has improved response rates, but only modestly and in certain subgroups of patients. Efforts to enhance the use of molecular biomarkers and develop new therapeutic targets to improve response rates and ultimately overall survival are ongoing. Finally, care of NSCLC patients requires input and coordination of a multidisciplinary clinical team; current guidelines specify consultation with such teams but do not provide a framework for collaboration. Oncologists require insight on the selection of appropriate courses of therapy for patients with advanced NSCLC to maximize rate and durability of response. Additionally, oncologists require practical application of biomarker expression to identify subsets of patients most likely to benefit from particular therapies.
     
    Target Audience
    This activity has been designed to meet the educational needs of medical oncologists, surgical oncologists, radiation oncologists, clinical pathologists, and other health care professionals involved in the care and treatment of patients with NSCLC.

    Accreditation Statement
    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Curatio CME Institute and H. Lee Moffitt Cancer Center & Research Institute. Curatio CME Institute is accredited by the ACCME to provide continuing medical education for physicians.
     
    Credit Designation
    Curatio CME Institute designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
     
    Method of Participation
    There are no fees for participating in this CME activity. To receive credit during the period to August 23, 2011, participants must (1) read the learning objectives and disclosure statements, (2) complete the educational activity, and (3) complete the posttest and activity evaluation form, including the certificate information section.
     
    To obtain a certificate, participants must receive a score of 70% or better on the post-test. The post-test can be accessed at the end of the activity. Please e-mail any questions to cmeinfo@curatiocme.com.
     
    Medium
    The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
     
    Disclosure
    In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. 
     
    Curatio CME Institute
    Denise C. LaTemple, PhD, President, Curatio CME Institute, has disclosed no relevant financial relationships.
    Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
    Derek Warnick, CME Director, has disclosed no relevant financial relationships.
     
    H. Lee Moffitt Cancer Center & Research Institute
    Claire A. Modarelli, Manager, has disclosed no relevant financial relationships.
     
    Disclaimer
    The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient's medical condition.
     
    Unapproved Product Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, H. Lee Moffitt Cancer Center & Research Institute, and Lilly do not recommend the use of any agent outside the labeled indications.
     
    The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, H. Lee Moffitt Cancer Center & Research Institute, or Lilly. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Policy on Privacy and Confidentiality
    Curatio CME Institute collects the information provided by the user. The information is used to notify users about upcoming programs and educational information that may be of interest. The information is not shared or used for commercial purposes unless prior permission has been granted by the user.
     
    Curatio CME Institute may collect standard Web traffic data such as time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation of and issuance of certification for CME/CE tests. By participating in the Web-based activity, the user agrees that Curatio CME Institute has full permission to provide this minimum subset of information to the third parties as required by law.